FRPT vs SPB: How Freshpet and Spectrum Brands Holdings, Inc. Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SPB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FRPT and SPB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FRPT and SPB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Freshpet makes fresh, refrigerated food for dogs and cats and sells it through company-owned branded refrigerators placed inside retailers including Walmart, Target, Kroger, Costco, Publix, Petco, PetSmart and Tractor Supply. The model is unusual for a food company: Freshpet buys, installs, services and owns the fridge, which is both the distribution asset and the merchandising unit, and it manufactures nearly everything itself across three kitchen complexes in Bethlehem, Pennsylvania and Ennis, Texas. That vertical integration is why capital spending has run heavy for a decade (roughly $150 million planned in 2026) and why operating leverage arrives in steps rather than smoothly, as new lines come online and then fill up.

Full FRPT guide

Spectrum Brands Holdings owns and operates consumer brands across three reporting segments. Global Pet Care is the largest and includes Tetra and Marineland in aquatics plus FURminator, Nature's Miracle, DreamBone and 8-in-1 in companion animal. Home & Garden sells household pest and lawn control under Spectracide, Cutter, Hot Shot and Black Flag, a business that swings with spring weather and retailer order timing. Home & Personal Care covers small kitchen and grooming appliances under Remington, George Foreman and Russell Hobbs. The company does not own premium category leaders in most of these aisles. It owns the value and mid-tier positions, sold largely through Walmart, Amazon, Home Depot, Lowe's and other big-box retail, which makes shelf space and retailer inventory decisions a bigger swing factor than brand pricing power.

Full SPB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• FRPT drivers: Household penetration and buy rate, not price; Capacity coming online at Ennis.
• SPB drivers: Pet care as the growth and margin anchor; Home & Garden operating leverage when the weather cooperates.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The competitive set changed in 2025 and 2026 and has not settled: The Farmer's Dog moved onto Walmart.com, Hill's launched a fresh line, and Costco introduced Kirkland fresh pet food, all attacking the premium position Freshpet built alone. For SPB, spectrum's brands sit largely in value and mid-tier price points sold through a handful of very large retailers, so a shelf-reset decision at Walmart or a retailer inventory correction can move a quarter more than consumer demand does.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick FRPT if you believe its drivers more; SPB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FRPT and SPB guides.

FRPT. The gap between the operating result and the share price is the whole story here: the stock sits roughly 55% below its late-2024 peak while revenue, margins and cash flow have all improved. Reported net income figures are noisy because of tax valuation-allowance movements and a ~$4.5 million equity-investment gain in Q2 2026, so adjusted EBITDA is the cleaner comparison across periods. Anyone sizing the multiple should note that heavy capex means EBITDA overstates free cash flow, and that ~$150 million of annual capital spending is a real claim on it.

SPB. The multiple looks ordinary for a consumer staples name until you notice the share count. About 23 million shares outstanding against roughly $2.8 billion of revenue means the enterprise trades at a fraction of one times sales, while the earnings multiple sits in the high teens because margins are thin at the consolidated level. Guidance for fiscal 2026 calls for net sales flat to up low single digits, adjusted EBITDA up low to mid single digits, and roughly 50% conversion of adjusted EBITDA into adjusted free cash flow. The stock has run from a 52-week low near $50 to about $88, close to its $92 high, so the discount that attracted value buyers a year ago is materially narrower.

Headline figures (approximate, August 2026): FRPT shows revenue (ttm) ~$1.18 billion, with Q2 2026 net sales of ~$305.6 million, up ~15.5% year over year, 2026 guidance Net sales growth of ~10% to 12% (~$1.21 billion to $1.23 billion), raised in August 2026 from ~8% to 11%, adjusted ebitda ~$52.2 million in Q2 2026 (~17.1% margin); full-year guidance raised to ~$210 million to $220 million, margins Adjusted gross margin ~48.6% in Q2 2026 versus ~46.9% a year earlier; guided to improve ~100 to 150 basis points for the year; SPB shows revenue (ttm) ~$2.82 billion, down ~3.8% year over year, fiscal q2 2026 net sales ~$709 million, up ~4.9% reported and ~1.5% organic, fiscal q2 2026 adjusted ebitda ~$84 million, up ~$12.7 million year over year, net income / eps (ttm) ~$126 million and ~$5.24 per share.

FRPT and SPB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FRPT and SPB exposure against your real portfolio. It is not an investment adviser.